Pubblicazioni

Approfondimenti generali

: ESMO Clinical Practice Guidelines: Haematological Malignancies [Apri]
: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2018 [Apri]
: ClinicalTrial.gov. A service of the U.S. National Institutes of Health [Apri]

Referenze bibliografiche specifiche

: Grafone T, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev 2012; 6:e8 [Apri]
: Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program 2013; 2013:220-226 [Apri]
: Barragán E, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96:1470-1477 [Apri]
: Gorin NC, et al. Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission. Haematologica 2013; 98:e12 [Apri]
: Döhner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-447 [Apri]